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Human cytomegalovirus (CMV) serology is posi-
tive in nearly two-thirds of individuals in the United
States, but cutaneous manifestations of infection are
exceedingly rare.1-4 To our knowledge, few cases of
CMV-induced cutaneous manifestations have been
reported and most commonly occur in immunocom-
promised populations. Here we report a case of
localized sclerodermoid skin changes in an immu-
nocompetent patient with CMV infection.Fig 1. Hyperpigmented, tender, indurated suprapatellar
dermal plaques on bilateral lower extremities.CASE REPORT
A 27-year-old incarcerated African-American man
with history of polysubstance abuse was transferred
to a university medical center for pancytopenia
workup with 5 weeks of fevers and abdominal
pain. He was previously healthy and was previously
treated with nonsteroidal anti-inflammatory drugs
while in prison, which caused acute renal failure
requiring intermittent hemodialysis before transfer.
Fevers continued, and the patient noted approxi-
mately 2 weeks of asymmetric polyarthralgias with
extreme suprapatellar tenderness and tightness
bilaterally and an identical 2-day history involving
the right lateral upper extremity. Examination found
mildly hyperpigmented, tender, indurated supra-
patellar and right lateral upper extremity dermal
plaques (Fig 1). Review of systems was otherwise
unremarkable with pertinent negatives including
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Case Reports 2016;2:119-21.heartburn, and numbness/pain in distal extremities
when exposed to cold.
On admission, the patient was pancytopenic with
a white blood cell count of 4.66 K/L, hemoglobin of
7.8 g/dL, hematocrit of 24.2%, and platelet count of
138 K/L. An extensive rheumatologic, hematologic/
oncologic, and infectious workup was positive for
CMV by blood specimen allele-specific quantitative
polymerase chain reaction (PCR) and an elevated
erythrocyte sedimentation rate (37 mm/h) and
C-reactive protein level (2.78 mg/dL). CMV by PCR2352-5126
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Fig 2. A, Sclerotic collagen bundles without evidence of granulomatous inflammation.
B, Sclerotic collagen bundles with evidence of perivascular infiltration. (A and B,
Hematoxylin-eosin stain; original magnifications: A, 32; B, 340.)
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with nonreactive CMV IgM and reactive CMV IgG
antibodies. Results of serologic testing for HIV,
hepatitis B, hepatitis C, syphilis, Epstein-Barr virus,
human T-cell lymphotropic virus, tick-borne illness,
and parasitic infection were negative. Results
for antinuclear antibodies and anti-Smith, antie
double stranded DNA, anticentromere, antieSCL
70, anticyclic citrullinated peptide, and antineutro-
phil cytoplasmic antibodies were all negative.
Immunoglobulins and C3 and C4 levels were within
normal limits, and genetic testing by PCR for
BCR-ABL and JAK2 V617F mutations were negative
for chronic myelogenous leukemia and myelopro-
liferative disorders, including polycythemia vera,
essential thrombocytopenia, and myelofibrosis. An
angiotensin-converting enzyme level was mildly
elevated, a chest radiograph was unremarkable,
and chest/abdomen/pelvis computed tomography
with contrast demonstrated mild mediastinal, axil-
lary, inguinal, and external iliac lymphadenopathy,
likely explained by active CMV infection.
A skin punch biopsy was performed at the right
upper extremity dermal plaque. Hematoxylin-eosin
staining found sclerosing dermatitis suggestive of
localized sclerodermoid change (Fig 2, A and B). The
upper dermis showed a sparse superficial lympho-
cytic infiltrate with few melanophages, but no
evidence of granulomatous inflammation suggestive
of cutaneous sarcoid or panniculitis was found
(Fig 2, A and B). Immunoperoxidase staining of the
specimen for CMV was negative. CMV PCR of the
skin was not performed, as the positive serologic
testing combined with the previously described
sclerosis and perivascular infiltration were consi-
dered confirmatory.
Bone marrow biopsy found a normocytic, nor-
mochromic anemia with moderately hypocellularmarrow (20% to 30%) and a universal decrease in
hematopoiesis, which was nonsuggestive of a
neoplastic or myelofibrotic process but rather
favored infectious versus inflammatory etiology.
The patient started intravenous ganciclovir as an
inpatient and transitioned to valganciclovir, 900 mg
by mouth twice daily for 2 weeks as an outpatient.
Follow-up 2 weeks postdischarge found complete
resolution of the skin-related pain, while the hyper-
pigmentation and indurated plaques remained.
DISCUSSION
Cutaneous manifestations of CMV infection are
uncommon but have been reported with wide vari-
ability as ulcers, purpura, nodules, maculopapular
eruptions, necrotic papules, verrucous plaques, pete-
chiae, pustules, and localized sclerodermoid change,
as in this case report.4-6 The association between CMV
infection and the immunocompromisedhost has been
clearly documented in the literature, and it is under-
stood that the presence of CMV-induced cutaneous
pathology portends a poor prognosis with mortality
rates studied up to 85% within 6 months.4,5,7,8 In
immunocompetent individuals, case reports show an
association between CMV infection and onset of
cutaneous and systemic scleroderma in addition to
the presentations above.6,9
CMV was initially low on our list of differential
diagnoses because of our patient’s immunocompe-
tence.2,8 Myelofibrosis, leukemia, and sarcoidosis
were early considerations ruled out by peripheral
blood smear as well as bone marrow and dermal
plaque biopsies. Systemic sclerosis was eliminated
from consideration because of a lack of systemic
findings and negative antibody titers.
CMV is known to incite vascular pathology, which
likely contributed to the localized skin findings in
our patient. Previous studies indicate that CMV
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ment of scleroderma, specifically human CMV late
protein UL94 and NAG-2, which has been associated
with sclerodermoid skin changes.9-11 CMV also in-
duces transforming growth factor beta to upregulate
profibroblastic cytokines and increases tumor ne-
crosis factor signaling pathway activity, thereby
upregulating vascular endothelial growth, adhesion
molecule function, vascular endothelial apoptosis,
and fibroblast activity.9,10
Clinically significant CMV infections may arise in
both immunocompromised and immunocompetent
populations with variable cutaneous manifestations.
Our report highlights a rare case of CMV-induced
proximal extremity sclerodermoid skin changes in an
immunocompetent host without signs of systemic
sclerosis. Detailed history taking may be particularly
helpful in elucidating this diagnosis, as with our
patient, whose risk for contracting CMV and
other immunocompromising conditions is increased
because of incarceration. Nevertheless, antiviral treat-
ment resulted in complete resolution of pain-related
skin symptoms, although the dermal plaques remain.
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